NCT04997135已完成不适用
Clinical Evaluation of Therapeutic Meibomian Gland Expression
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Meibomian Gland Appearance
研究概览
简要总结
This will be a single centre pilot study to evaluate appearance of the Meibomian glands.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- •Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- •Be between 18 and 60 (inclusive) years of age at the time of screening. Inclusion Criteria at Baseline Evaluation.
- •The subject must have visual acuity of 0.2 high contrast logMAR or better in their current correction or unaided in each eye.
- •The subject must have at least 10 Meibomian glands yielding liquid secretion (MGYLS) in central lower eyelid region in each eye.
- •The subject eyelids must be easy to evert, at the Investigator's discretion.
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Be currently pregnant or breastfeeding.
- •By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See Section 9.1 for additional details regarding excluded systemic medications.
- •Have any known hypersensitivity or allergic reaction to any of the known ingredients in the anesthetic (proxymetacaine hydrochloride) or sodium fluorescein.
- •Have a history of cardiac disease or hyperthyroidism.
- •Have had any previous ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, cataract etc.)
- •Have participated in any ophthalmic clinical trial within 14 days prior to study enrolment.
- •Be an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- •Have a history of amblyopia or strabismus.
- •Have a history of contact lens wear. A trial period (up to one week) in the past is allowed.
- •Wear eye makeup on the days of the study visits.
- •Have clinically significant (grade 3 or higher on the Efron grading scale) slit lamp findings (e.g., corneal edema or neovascularization, conjunctival or limbal redness) or any other abnormality which would normally contraindicate participation in the study.
- •Have any ocular infection.
- •Have central lower eyelid Meibomian gland atrophy that exceeds 25%.
结局指标
主要结局
Meibomian Gland Appearance
时间窗: up to 2-week follow-up
Meibomian gland appearance will be evaluated on both eyes using a custom image analysis algorithm, which calculates length ratio, width, area, intensity, tortuosity, and contrast
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Dynamic Characterisation of Meibomian Gland StructureVisual AcuityNCT04649606Johnson & Johnson Vision Care, Inc.25
已完成
不适用
Treatment of Meibomian Gland Dysfunction Prior to Cataract SurgeryBlepharitisDry Eye SyndromeNCT01808560TearScience, Inc.34
已完成
4 期
Intraductal Meibomian Gland Probing TrialMeibomian Gland DysfunctionNCT02256969Joseph B. Ciolino, MD45
已完成
不适用
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens WearersMeibomian Gland DysfunctionDry EyeNCT02102464TearScience, Inc.55
已完成
不适用
Meibomian Gland Dysfunction TreatmentDry EyeMeibomian Gland DysfunctionNCT04229888Indiana University14